CN120136844A - 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法 - Google Patents

类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法 Download PDF

Info

Publication number
CN120136844A
CN120136844A CN202510314712.9A CN202510314712A CN120136844A CN 120136844 A CN120136844 A CN 120136844A CN 202510314712 A CN202510314712 A CN 202510314712A CN 120136844 A CN120136844 A CN 120136844A
Authority
CN
China
Prior art keywords
myocardial infarction
subject
mcb
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510314712.9A
Other languages
English (en)
Chinese (zh)
Inventor
B·W·奥马利
D·M·罗纳德
Y·宋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of CN120136844A publication Critical patent/CN120136844A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN202510314712.9A 2018-08-29 2019-08-29 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法 Pending CN120136844A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862724281P 2018-08-29 2018-08-29
US62/724281 2018-08-29
US201962825358P 2019-03-28 2019-03-28
US62/825358 2019-03-28
PCT/US2019/048703 WO2020047186A1 (en) 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
CN201980071611.6A CN112955217B (zh) 2018-08-29 2019-08-29 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980071611.6A Division CN112955217B (zh) 2018-08-29 2019-08-29 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法

Publications (1)

Publication Number Publication Date
CN120136844A true CN120136844A (zh) 2025-06-13

Family

ID=67982135

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510314712.9A Pending CN120136844A (zh) 2018-08-29 2019-08-29 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法
CN201980071611.6A Active CN112955217B (zh) 2018-08-29 2019-08-29 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980071611.6A Active CN112955217B (zh) 2018-08-29 2019-08-29 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法

Country Status (7)

Country Link
US (4) US10875841B2 (https=)
EP (1) EP3843843A1 (https=)
JP (3) JP7495138B2 (https=)
CN (2) CN120136844A (https=)
AU (2) AU2019333119B2 (https=)
CA (1) CA3110839A1 (https=)
WO (1) WO2020047186A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120136844A (zh) * 2018-08-29 2025-06-13 贝勒医学院 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法
KR20230093329A (ko) 2020-10-28 2023-06-27 베이롤 칼리지 오브 메드신 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화
WO2025240566A1 (en) * 2024-05-17 2025-11-20 Baylor College Of Medicine Small molecule steroid receptor coactivator stimulators for use in repairing tissue

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
CA2393440A1 (en) 1999-12-03 2001-06-07 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20070010488A1 (en) 2005-04-13 2007-01-11 Khairia Youssef Compounds for modulating cell proliferation
CN102381951B (zh) 2007-01-22 2013-09-04 温州医学院生物与天然药物开发中心有限公司 含环己酮的姜黄素单羰基结构类似物及其用途
EP2170311A4 (en) 2007-05-16 2011-10-19 Avalon Pharmaceuticals COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
US20100197584A1 (en) 2007-07-27 2010-08-05 Research Foundations of the City University of- New York Use of curcumin to block brain tumor formation in mice
WO2009144220A1 (en) 2008-05-29 2009-12-03 Universite Libre De Bruxelles Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
US8420118B2 (en) * 2009-09-10 2013-04-16 The Board Of Regents Of The University Of Oklahoma Anionic lipids and lipid nano-structures and methods of producing and using same
WO2011029359A1 (zh) 2009-09-12 2011-03-17 温州医学院 含11β-羟基甾体脱氢酶1双重调节剂的药物及其应用
JP2011074024A (ja) * 2009-09-30 2011-04-14 Shiseido Co Ltd ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物
WO2011127333A2 (en) 2010-04-09 2011-10-13 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012021692A1 (en) 2010-08-11 2012-02-16 Rutgers, The State University Of New Jersey Curcumin analogs and methods of use thereof
CN102153508B (zh) * 2010-10-08 2013-01-09 福建医科大学 3,5-(e)-二亚苄基-n-环丙基哌啶-4-酮及其在制备治疗抗肿瘤药物中的应用
CN103012088B (zh) 2012-11-28 2017-01-11 江苏药兴医药股份有限公司 α-(3,5-二甲氧基苯亚甲基)-α'-烃基亚甲基环酮及其制备方法
ITMI20130075A1 (it) 2013-01-21 2014-07-22 Altergon Sa Combinazione orale per la prevenzione e il trattamento di patologie vescicali, pelviche e dell¿apparato uro-genitale
CN103181922A (zh) * 2013-04-02 2013-07-03 温州医学院 一类含哌啶酮的单羰基姜黄素类化合物在制备抗炎药物中的应用
WO2016109470A1 (en) 2014-12-30 2016-07-07 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
WO2017062751A1 (en) * 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
CN106083704B (zh) * 2016-06-06 2018-07-27 福建医科大学 3,5-(E)-二芳亚甲基-N-环丙基哌啶-4-酮类化合物作为Hsp90抑制剂的应用
EP3713916A1 (en) * 2017-11-20 2020-09-30 Kiakos, Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
CN120136844A (zh) * 2018-08-29 2025-06-13 贝勒医学院 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法

Also Published As

Publication number Publication date
JP2024102352A (ja) 2024-07-30
EP3843843A1 (en) 2021-07-07
AU2019333119B2 (en) 2025-06-05
JP2021534221A (ja) 2021-12-09
US20230357200A1 (en) 2023-11-09
CN112955217B (zh) 2025-04-08
AU2025226726A1 (en) 2025-09-25
CN112955217A (zh) 2021-06-11
US20250282755A1 (en) 2025-09-11
AU2019333119A1 (en) 2021-03-18
US12338229B2 (en) 2025-06-24
JP2025183370A (ja) 2025-12-16
WO2020047186A1 (en) 2020-03-05
JP7495138B2 (ja) 2024-06-04
US10875841B2 (en) 2020-12-29
JP7777263B2 (ja) 2025-11-28
US11708350B2 (en) 2023-07-25
US20200071300A1 (en) 2020-03-05
US20210115017A1 (en) 2021-04-22
CA3110839A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
JP7777263B2 (ja) ステロイド受容体コアクチベーター－３の小分子刺激因子ならびに心臓保護剤及び／または血管再生剤としてのそれらの使用方法
Witek et al. Liver cell–derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells
She et al. Hippo pathway activation mediates chemotherapy-induced anti-cancer effect and cardiomyopathy through causing mitochondrial damage and dysfunction
KR102342620B1 (ko) 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
Zhang et al. Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria
WO2011133879A2 (en) Combination therapies with mitochondrial-targeted anti-tumor agents
Vivas-Mejia et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
RU2637372C2 (ru) Средство для лечения фиброза кишечника
Lan et al. Glycine suppresses kidney calcium oxalate crystal depositions via regulating urinary excretions of oxalate and citrate
US20250339445A1 (en) Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke
Jiao et al. Mesenchymal stem cells‐derived extracellular vesicle‐incorporated H19 attenuates cardiac remodeling in rats with heart failure
WO2023038027A1 (ja) セノリシス薬のスクリーニング方法及びセノリシス薬
Gopinath et al. Doxorubicin-mediated apoptosis in glioma cells requires NFAT3
Liu et al. Puerarin exerts an inhibitory effect on inflammatory infiltration in the cardiac tissue of EAM mice by regulation of the TNF-α/CCL2/CCR2 signal pathway
CN102008715B (zh) 抗肿瘤的MA-TNFα药物组合物及其应用
Bai et al. Chiral ruthenium (II) complex Δ-[Ru (bpy) 2 (o-FMPIP)](bpy= bipyridine, o-FMPIP= 2-(2′-trifluoromethyphenyl) imidazo [4, 5-f][1, 10] phenanthroline) as potential apoptosis inducer via DNA damage
Peng et al. de-O-methyllasiodiplodin from Ludwigia hyssopifolia causes death of human liver cancer cells through the mitochondrial apoptotic, Akt/NF-κB and STAT3 pathway in vitro
CN111840557A (zh) 磷酸二酯酶4抑制剂的用途
JP7759032B2 (ja) 脳血管攣縮抑制剤
Zhang et al. E-Selectin-Targeted Nanomicelles via Sialic Acid Conjugation for Anti-Inflammatory Efficacy and Alleviating the Progression of Metabolic-Associated Steatotic Liver Disease
Zhou et al. Atractylenolide I mitigates Alzheimer’s disease pathology in ApoE–/–mice via ARG1/nNOS axis and lipid homeostasis regulation
WO2025162246A1 (zh) 防治多发性骨髓瘤的甲磺酸普依司他及其类似物联合用药物及其用途
Lei et al. Ligustilide Targets SMAD3, Showing Immunomodulatory Effects in Improving Atherosclerosis
KANNAIYAN IDENTIFICATION OF A NOVEL AGENT THAT CAN SUPPRESS PROLIFERATION, INDUCE APOPTOSIS AND OVERCOME CHEMORESISTANCE IN MULTIPLE MYELOMA
CN118416226A (zh) Ku复合物抑制剂在靶向肿瘤中的治疗策略及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination